KYZATREX (Testosterone Undecanoate) Patent Expiration, LOE Window & CMS Spending
KYZATREX (Testosterone Undecanoate) by Marius: FDA Orange Book core substance LOE 2041-03-29, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Marius |
| FDA Application & Pathway | N213953 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2041-03-29 |
| Last Listed Patent or Exclusivity Date | 2041-03-29 |
| Orange Book Patents (*PED Extensions) | 18 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $0 |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $0 |
| Reported Wholesale Price Change (CA SB 17) | 4 WAC filings (max 151.6% 2-yr change) |